Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SeaStar Medical Holding ( (ICU) ) has provided an announcement.
On September 24, 2025, SeaStar Medical announced that the independent Data Safety Monitoring Review Board (DSMB) recommended the continuation of the NEUTRALIZE-AKI pivotal trial for its Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB found no device-related safety issues and suggested increasing the total patient enrollment to 339 to strengthen the trial’s statistical power. This recommendation supports the potential clinical benefit of the SCD therapy, which aims to improve outcomes for critically ill patients by reducing mortality and dialysis dependency. SeaStar Medical is actively working to accelerate patient enrollment and expects to complete it by the end of 2026.
The most recent analyst rating on (ICU) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on SeaStar Medical Holding stock, see the ICU Stock Forecast page.
Spark’s Take on ICU Stock
According to Spark, TipRanks’ AI Analyst, ICU is a Underperform.
SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.
To see Spark’s full report on ICU stock, click here.
More about SeaStar Medical Holding
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The company’s Selective Cytopheretic Device (SCD) therapy, marketed under the brand name QUELIMMUNE, is the first FDA-approved product for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients. SeaStar Medical is conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT).
Average Trading Volume: 3,305,682
Technical Sentiment Signal: Sell
Current Market Cap: $34.61M
For an in-depth examination of ICU stock, go to TipRanks’ Overview page.